ERBB2 activating mutations across all domains were largely clonal (ranging from 73.1%–92.0% of ERBB2 mutations across cancer types), indicating they are often likely truncal in the tumor types studied (Supplementary Fig. S6). Here, ERBB2 is linked to neoplasm.